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Background: Inhaled corticosteroid use is associated with increased rates of pneumonia in 
COPD patients. The underlying mechanism is unknown, although recent data suggest that pneu-
monia is more frequent in patients treated with fluticasone propionate (FP) than budesonide. 
Macrophages and neutrophils from COPD patients are deficient in clearing bacteria, and this 
might explain increased bacterial colonization in COPD. Inhaled corticosteroid may further sup-
press this response; therefore, we examined the effect of FP and budesonide on phagocytosis of 
common respiratory pathogens by monocyte-derived macrophages (MDMs) and neutrophils.
Methods: MDMs from COPD patients (n=20–24) were preincubated with FP or budesonide 
for 1 or 18 hours, after which phagocytosis of fluorescently labeled inert beads or heat-killed 
Haemophilus influenzae/Streptococcus pneumoniae were measured fluorimetrically after 1 or 
4 hours. Additionally, CXCL8, IL6, and TNFα concentrations in supernatants by ELISA, 
MDM-scavenger-receptor expression by flow cytometry, and MDM ability to kill bacteria were 
measured. Neutrophils from COPD patients (n=8) were preincubated with corticosteroids for 
1 hour and bacteria phagocytosis measured by flow cytometry.
Results: After 1 hour’s preincubation, neither corticosteroid altered MDM phagocytosis of beads 
or H. influenzae; however, budesonide (10−7 M) increased S. pneumoniae phagocytosis by 23% 
(P0.05). After 18 hours’ preincubation, neither corticosteroid altered MDM phagocytosis of 
any prey, although H. influenzae phagocytosis by budesonide was significantly greater com-
pared to FP at 10−6 and 10−5 M (P0.05). The 1-hour preincubation with either corticosteroid 
inhibited bacteria-induced CXCL8 release (at 10−7 and 10−5 M, P0.05); however, this effect 
was lost at 18-hour preincubation. There was no change in receptor expression, bacterial killing, 
or neutrophil phagocytosis by either corticosteroid.
Conclusion: These data suggest that dissolved FP and budesonide do not have an overall effect 
on MDM or neutrophil phagocytosis of bacteria.
Keywords: COPD, macrophage, neutrophil, fluticasone propionate, budesonide
Introduction
Inhaled corticosteroids (ICSs) are now prescribed to 70% of patients with COPD.1 
ICSs used in COPD patients (mostly in combination inhalers with long-acting 
β
2
-adrenergic agonists [LABAs]) have been shown to improve patients’ symptoms 
and health status, reduce decline in FEV
1
, and decrease exacerbation rates.2 These 
patients are predominantly prescribed ICSs such as fluticasone propionate (FP) or 
budesonide; however, randomized controlled trials have suggested that inhaled FP 
alone or in combination with the LABA salmeterol is associated with an increased rate 
of pneumonia.3–7 On the other hand, most double-blind, randomized controlled studies 
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with budesonide treatment alone or in combination with 
the LABA formoterol reported no increased risk of pneu-
monia when compared with formoterol alone or placebo.8 
Furthermore, large observational, population-based studies 
in real-world, clinical practice with COPD patients have 
suggested a higher risk of pneumonia for therapy with FP 
than with budesonide.9–12 Similarly, a recent evaluation of 
meta-analyses that considered the risk of pneumonia related 
to treatment of COPD patients with FP or budesonide showed 
an association with FP causing a statistically significant 
increased risk of pneumonia, whereas budesonide showed 
no association.13 This finding is of increased importance, as 
patients with COPD who are hospitalized with pneumonia 
have been shown to have increased mortality compared to 
those without COPD.14,15
It remains unclear why different ICSs have differential 
effects on the increased risk of pneumonia. One reason may 
be a greater suppression of macrophage and/or neutrophil 
functions mediated by FP, such as phagocytosis and/or 
bacterial killing. The immunosuppressant potency of FP can 
be up to tenfold greater than that of budesonide, as reported 
for in vitro inhibition of innate immunoresponse to bacterial 
triggers in human alveolar macrophages.16 Furthermore, sup-
pression of local immunity by FP in the airways/lung may 
be prolonged because inhaled FP resides for several hours in 
the airway lining fluid and mucus, most likely in the form of 
undissolved particles, which only dissolve slowly.17,18 This 
contrasts with budesonide, which is completely dissolved 
and absorbed into the airway tissue within a few minutes 
and thus quickly cleared from the airway lumen.13,17,18 
Additionally, the clearance of particulate FP by phagocytic 
mechanisms may lead to extremely high concentrations of 
the drug residing within the phagolysosomes, which may 
further impair phagocytosis/killing of bacteria, resulting in 
impaired/delayed bacterial clearance.
Alveolar macrophages play a major role in removal of 
potentially pathogenic microorganisms via phagocytosis and 
are essential for maintenance of the pulmonary environment.19 
One reason for the increased incidence of bacterial infections 
in the respiratory tract of COPD patients might be failure of 
macrophages to clear pathogens because of reduced phago-
cytosis, due to chronic activation.20 We have shown that 
this defect can also be observed in macrophages obtained 
from blood-derived monocytes.21 These monocyte-derived 
macrophages (MDMs) from patients with COPD exhibit 
reduced phagocytosis of both Gram-negative and Gram-
positive bacteria, but not inert beads, thereby mimicking the 
effect observed in alveolar macrophages. A recent study in 
COPD patients has shown that long-term therapy with FP 
increased sputum bacterial load and relative abundance of 
Haemophilus influenzae and Streptococcus pneumoniae, the 
key bacteria involved in development of pneumonia, indicat-
ing a potential link between macrophage function and the 
effects of FP in COPD.22
We hypothesized that the higher rates of pneumonia asso-
ciated with FP compared to budesonide are caused by greater 
inhibition of macrophage or neutrophil function and defective 
clearance of bacteria. Therefore, the aim of the study was to 
investigate the phagocytic ability and immunoresponse of 
MDMs and neutrophils from COPD patients treated in vitro 
with FP or budesonide compared to drug-vehicle-treated 
control cells.
Methods
subject selection
COPD subjects were recruited from the National Heart and 
Lung Institute, Royal Brompton Hospital, London (UK). 
All subjects gave written, informed consent as approved by 
the London–Chelsea NRES committee. Demographic data 
are presented in Table 1. All COPD subjects were clinically 
stable and had not experienced any exacerbations for at least 
4 weeks prior to inclusion in the study. All were treated 
with ICSs.
Cell culture
Monocytes were isolated from peripheral blood mononu-
clear cells using a Percoll gradient and adherence technique, 
followed by culture in 2 ng/mL granulocyte-macrophage 
colony-stimulating factor (R&D Systems, Minneapolis, 
MN, USA) for 12 days to generate MDMs as described 
previously.21 Neutrophils were isolated from whole blood 
following sedimentation using 6% (w:v) dextran fol-
lowed by Percoll density-gradient separation as reported 
previously.23
Table 1 Demographics of COPD subjects
Demographics COPD patients 
(n=29)
sex, male:female (n) 15:14
age (years) 69±1.4
smoking history (pack-years) 28.5±4.3
FeV1 (l) 1.3±0.1
FeV1 (% predicted) 56.8±2.7
FVC (l) 2.7±0.2
FVC (% predicted) 84.5±4.7
FeV1:FVC ratio 0.50±0.03
Note: Data presented as mean ± seM, except where indicated.
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Cell treatment
MDMs and neutrophils were left untreated or exposed to 
FP, budesonide, or 0.1% (v:v) dimethyl sulfoxide (DMSO; 
vehicle) for 1 hour or 18 hours prior to the addition of 
phagocytic prey and remained in the media throughout the 
experiment.
Bacterial culture and labeling for 
phagocytosis assays
Nontypeable H. influenzae strain 1479 and S. pneumoniae 
serotype 9 V strain 10,692 were cultured and heat-killed at 
70°C for 2 hours. Bacteria were fluorescently labeled using 
Alexa Fluor 488 NHS ester (2 mg/mL in DMSO) in the dark 
at room temperature overnight. Labeled bacteria were washed 
repeatedly in PBS to remove unbound labeling, resuspended 
in PBS, and stored at −20°C.
Phagocytosis assays
Fluorescently labeled polystyrene beads or bacteria were 
added to cells and incubated for the times indicated. Cells 
were washed with PBS and extracellular particle fluorescence 
quenched by adding Trypan blue (2% w:v) for 1 minute. 
Excess fluid was removed and fluorescence determined using 
an excitation at 480 nm and emission 520 nm. The relative 
amount of bacteria phagocytosed is reported as relative 
fluorescent units (RFUs). Cell viability was measured using 
MTT assay. None of the treatments at any time of analysis 
had any effect on cell viability (Figure S1).
Cytokine analysis
ELISAs were performed to measure concentrations of 
TNFα, CXCL8, IL6, and IL10 in cell supernatants accord-
ing to the manufacturer’s instructions (R&D Systems). The 
lower limit of detection for all cytokines was 31 pg/mL.
scavenger-receptor analysis
After phagocytosis, cells were transferred to fluorescence- 
activated cell-sorting (FACS) tubes, washed, and resus-
pended in 4% (v:v) paraformaldehyde. Cells were blocked 
with 1% human serum, then washed and resuspended in 
FACS buffer (PBS +0.5% [w:v] BSA +0.05% [w:v] sodium 
azide). Cells were incubated for antibodies against TLR2 
Alexa Fluor 647, TLR4-PE, CD36-APC, CD206-PE, and 
CD163-PeCy7, or for MARCO staining, anti-MARCO pri-
mary antibody, followed by IgG
3
 Alexa Fluor 488 secondary 
antibody, for 30 minutes on ice, washed, and resuspended 
in PBS. Receptor expression was analyzed on a FACS 
Canto II (BD, Franklin Lakes, NJ, USA). Cells were gated 
using fluorescence minus-one gating. The amount of given 
types of receptor being expressed was analyzed by median 
fluorescence intensity and the percentage of cells expressing 
individual receptors also reported. Gating strategy is shown 
in Figure S2.
Bacteria-killing assay
Live bacteria were washed twice in PBS and sonicated. 
Bacteria were added to cells and incubated on ice for 1 hour to 
allow adherence, followed by incubation at 37°C for 4 hours. 
Cells were washed in PBS to remove excess bacteria, and 
incubated in benzylpenicillin (40 µg/mL) and gentamicin 
(20 µg/mL) for 30 minutes to kill extracellular bacteria that 
had not been phagocytosed. Cells were washed three times 
in PBS to remove antibiotics, and then incubated in 2% (v:v) 
saponin for 12 minutes to lyse cells. Samples were diluted 
and spread onto agar plates (Columbia agar with chocolate 
horse blood for H. influenzae, blood agar base two with horse 
blood for S. pneumoniae) and cultured overnight at 37°C. 
The next day, colonies were counted.
neutrophil-phagocytosis assay
Fluorescently labeled bacteria were added to neutrophils and 
incubated for the times indicated. Phagocytosis was stopped 
by adding 4% (w:v) paraformaldehyde and centrifugation 
of cells. Cells were resuspended in PBS and fluorescence 
assessed by flow cytometry. Data was analyzed using FlowJo 
software. Cell viability was measured using a Live/Dead 
cell-viability assay (Thermo Fisher Scientific, Waltham, 
MA, USA). The percentage of neutrophils that phagocy-
tosed bacteria is expressed as percentage phagocytosis and 
the amount of phagocytosed bacteria expressed as median 
fluorescence intensity.
statistical analysis
Data are shown as arithmetic mean ± SEM of independent 
donors. Statistical differences were determined using two-
way repeated-measure ANOVA with post hoc testing. Values 
of P0.05 were considered significant.
Results
effect of corticosteroids on phagocytosis 
by macrophages
In order to determine whether Corticosteroids (CSs) altered 
MDM phagocytosis, a series of experiments were devised 
using both inert beads and two common respiratory patho-
genic bacteria species associated with COPD: H. influenzae 
and S. pneumoniae. Firstly, MDMs were pretreated with FP 
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or budesonide (or DMSO vehicle) for 1 hour to determine 
the acute effects of CSs on phagocytic response after 1 and 
4 hours’ incubation with phagocytic prey. There were no 
significant effects of FP or budesonide (or drug vehicle) on 
phagocytosis of inert beads or bacteria after 1 hour’s incuba-
tion with phagocytic prey (Figure 1A–C). This was also the 
case after 4 hours’ incubation (Figure 1D–F), with the excep-
tion of 10−7 M budesonide, which significantly increased 
S. pneumoniae phagocytosis by 23% compared to vehicle 
control (P0.05, Figure 1F). This effect was not observed 
for the other concentrations of budesonide, and FP had no 
effect on S. pneumoniae phagocytosis. When the effects of the 
two CSs were compared, there was no statistically significant 
difference in phagocytosis at any drug concentration or for 
any prey (Figure 1). None of the treatments used significantly 
altered the viability of MDMs (Figure S1).
To determine the effects of chronic exposure to CSs, 
MDMs were pretreated with CSs for 18 hours. The phago-
cytic response of MDMs to inert beads or bacteria after 
1 or 4 hours’ incubation was not significantly affected by 
pretreatment with budesonide or FP (Figure 2), although a 
trend for approximately 20% increase of 4 hours phagocytosis 
of both H. influenzae and S. pneumoniae was observed for 
budesonide at the concentration range studied (Figure 2E 
and F). When the effects of CSs were compared with one 
another, there was a significant difference in 1-hour phago-
cytosis of H. influenzae between budesonide and FP at 
10−6 M (40% difference, P0.01) and 10−5 M (33% differ-
ence, P0.05), showing a greater degree of H. influenzae 
phagocytosis after 18 hours’ pretreatment with budesonide 
than with FP at these two high concentrations (Figure 2B). 
None of the treatments used significantly altered the viability 
of MDMs (Figure S1).
effect of corticosteroids on bacteria-
induced cytokine release
It is well known that CSs inhibit proinflammatory cytokine 
release by macrophages. In order to confirm that the con-
centrations of CSs used in these experiments were effec-
tive, CXCL8, IL6, TNFα, and IL10 were measured in cell 
supernatants after 1 or 4 hours’ phagocytosis of inert beads 
or bacteria. Cytokine concentrations in cell supernatants 
Figure 1 Effects of 1 hour’s pretreatment with fluticasone propionate or budesonide on phagocytosis of beads or bacteria at 1 hour and 4 hours.
Notes: Monocyte-derived macrophages from COPD patients (n=20–24) were untreated (UC [untreated control]) or pretreated for 1 hour with fluticasone propionate ( ), 
budesonide (), or drug vehicle (V) prior to incubation with either fluorescently labeled beads (A, D), H. influenzae (B, E) or S. pneumoniae (C, F) for 1 hour (A–C) or 4 hours (D–F). 
Phagocytosis was measured by fluorimetry and reported as relative fluorescent units (RFUs). Data are mean ± seM; *P0.05 for differences between budesonide and vehicle (V).
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were not significantly affected after 1 hour’s incubation of 
macrophages with inert beads or bacteria (data not shown). 
After 4 hours, incubation of MDMs with H. influenzae 
or S. pneumoniae significantly induced CXCL8, IL6, and 
TNFα release from macrophages (Figure 3A–C). Incuba-
tion with inert beads had no significant effect on cytokine 
release. Levels of IL10 were consistently below the limit of 
detection for any treatment (data not shown). Pretreatment 
with CS vehicle (DMSO) had no effect on cytokine release 
(Figure 3A–C). Compared to vehicle control, pretreatment 
with FP or budesonide for 1 hour caused a nonsignificant 
trend for concentration-dependent inhibition of inert bead-
induced CXCL8 (Figure 3D) and IL6 release (Figure 3E), 
but not TNFα release (Figure 3F). Pretreatment with FP for 
18 hours resulted in a similar trend for inert bead-induced 
CXCL8 release (Figure 4A), but not for IL6 (Figure 4B) or 
TNFα release (Figure 4C).
Compared to vehicle control, pretreatment with FP 
or budesonide for 1 hour caused a statistically significant 
concentration-dependent inhibition of CXCL8 release 
induced by H. influenzae, with maximal 34% inhibition by 
FP and 38% inhibition by budesonide (Figure 3G). A similar 
trend for approximately 30% maximal inhibition was seen for 
IL6 release (Figure 3H), but not for TNFα release (Figure 3I). 
These effects of 1 hour’s pretreatment with CSs on CXCL8 
and IL6 release were lost after 18 hours’ pretreatment 
(Figure 4D–E). However, approximately 20%–40% inhibi-
tion of TNFα release induced by H. influenzae was observed 
after 18 hours’ pretreatment with FP or budesonide over the 
whole concentration range studied, although these effects 
were not statistically significant (Figure 4F). Compared to 
vehicle control, pretreatment with FP or budesonide for 1 or 
18 hours had no significant effect on S. pneumoniae-induced 
CXCL8 (Figures 3J and 4G), IL6 (Figures 3K and 4H), or 
TNFα release (Figures 3L and 4I), although a trend for 
approximately 20% inhibition was seen for all cytokines.
effect of corticosteroids on macrophage-
scavenger-receptor expression
In order to determine whether the effects of CSs on 
cytokine release were due to alterations in scavenger-
receptor expression, CD36, CD206, CD163, TLR2, TLR4, 
and MARCO expression levels were analyzed on MDM 
surfaces after 4 hours’ exposure to phagocytic prey. 
Figure 2 Effects of 18 hours’ pretreatment with fluticasone propionate or budesonide on phagocytosis of beads or bacteria at 1 hour and 4 hours.
Notes: Monocyte-derived macrophages from COPD patients (n=22) were untreated (UC [untreated control]) or pretreated for 18 hours with fluticasone propionate ( ) 
or budesonide () at indicated concentrations or drug vehicle (V) prior to incubation with fluorescently labeled beads (A, D), H. influenzae (B, E) or S. pneumoniae (C, F) 
for 1 hour (A–C) or 4 hours (D–F). Phagocytosis was measured by fluorimetry and reported as relative fluorescent units (RFUs). Data are mean ± seM; #P0.05, ##P0.01 
between budesonide and fluticasone propionate.
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Following phagocytosis of H. influenzae, the percentage 
of cells expressing TLR2 and TLR4 significantly increased 
five- to sixfold and seven- to tenfold, respectively, compared 
to untreated cells (Tables 2 and S1), whereas there were no 
significant effects on the other receptors studied. There was 
no effect of S. pneumoniae phagocytosis on the percentage 
of cells expressing any of the receptors analyzed. MDM 
pretreatment for 1 or 18 hours with 10−5 M CSs did not 
significantly alter the percentage of cells expressing any of 
the receptors analyzed (Tables 2 and S1). The number of 
receptors being expressed by each cell was not altered by 
bacteria or pretreatment with CSs when analyzed by median 
fluorescence intensity (Tables 2 and S1).
effect of corticosteroids on bacterial 
killing by MDMs
Phagocytosis of bacteria may not be sufficient to clear invad-
ing organisms from the site of infection, as macrophages 
Figure 4 Effects of 18 hour's pretreatment with fluticasone propionate or budesonide on release of CXCL8, IL6, and TNFα induced by phagocytosis of beads or bacteria 
at 4 hours.
Notes: Monocyte-derived macrophages from COPD patients (n=12) were pretreated for 18 hours with fluticasone propionate ( ) or budesonide () at indicated concentrations 
or drug vehicle (V) prior to incubation with fluorescently labeled beads (A–C), H. influenzae (D–F), or S. pneumoniae (G–I) or bacteria for 4 hours. supernatants were analyzed 
by ELISA for CXCL8, IL6, or TNFα release. Data are percentage responses compared to vehicle control, expressed as mean ± seM, with no statistical differences observed.
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must also kill the internalized bacteria. In order to determine 
whether the bactericidal role of MDMs was also affected 
by CSs, the ability of MDMs to kill bacteria was measured. 
Neither FP, budesonide, nor drug vehicle (DMSO) had 
any significant effect on the killing of H. influenzae or 
S. pneumoniae at 4 hours postinfection (Figure 5).
effect of corticosteroids on phagocytosis 
by neutrophils
In order to determine whether the effect of CSs was limited 
to macrophages or whether other phagocytic cells could 
also be affected, phagocytosis by neutrophils (isolated from 
peripheral blood of COPD subjects) pretreated with CSs 
was also studied. Pretreatment of neutrophils with FP, 
budesonide, or drug vehicle (DMSO) for 1 hour had no sig-
nificant effect on the ability of neutrophils to phagocytose 
H. influenzae or S. pneumoniae (Figure S3) or the amount of 
bacteria phagocytosed (Figure S4) at any time point studied 
between 5 minutes’ and 60 minutes’ exposure to bacteria.
Discussion
Inhaled corticosteroids such as FP or budesonide are cur-
rently prescribed to COPD patients, mostly as combination 
inhalers with LABAs, to reduce exacerbation frequency; 
Figure 5 Effects of fluticasone propionate or budesonide on intracellular killing of Haemophilus influenzae or Streptococcus pneumoniae by MDMs from COPD patients.
Notes: MDMs from COPD patients (n=7) were untreated (UC [untreated control]) or pretreated with fluticasone propionate ( ) or budesonide () at indicated concentrations 
or drug vehicle (V), for 1 hour, and subsequently MDMs were incubated with H. influenzae (A) or S. pneumoniae (B) for 4 hours, antibiotics added to kill extracellular 
bacteria, MDMs lysed, and cell lysates plated on agar plates. after 12 hours, bacteria colonies were counted and colony-forming units (CFUs) calculated. Data presented as 
mean ± seM, with no statistical differences observed; n=10 for H. influenzae; n=7 for S. pneumoniae.
Abbreviation: MDMs, monocyte-derived macrophages.
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Table 2 Effects of 1 hour’s pretreatment with fluticasone propionate or budesonide on scavenger-receptor expression
Receptor NT HI HI + V HI + FP HI + Bud SP SP + V SP + FP SP + Bud
Percentage of cells expressing receptors
CD36 42 (12) 55 (9) 55 (8) 64 (8) 53 (9) 50 (10) 45 (11) 38 (9) 42 (10)
CD206 47 (13) 68 (8) 72 (6) 71 (8) 66 (10) 56 (12) 59 (9) 53 (9) 52 (10)
CD163 93 (2) 92 (6) 99 (1) 99 (1) 96 (2) 94 (1) 98 (1) 98 (1) 96 (2)
Tlr2 4 (1) 21 (5)** 24 (4) 25 (3) 17 (5) 11 (3) 6 (2) 5 (1) 5 (2)
Tlr4 3 (1) 22 (6)** 20 (4) 18 (4) 13 (5) 12 (4) 5 (1) 4 (1) 4 (2)
MarCO 24 (12) 45 (18) 41 (14) 33 (15) 33 (16) 61 (10) 69 (10) 62 (12) 59 (13)
Median fluorescence intensity
CD36 5.6 (0.8) 5.7 (0.7) 6.3 (1.0) 5.8 (0.7) 5.7 (0.7) 5.8 (0.8) 5.2 (0.6) 4.7 (0.5) 5.0 (0.6)
CD206 2.6 (0.4) 2.8 (0.5) 2.6 (0.4) 2.7 (0.4) 2.5 (0.3) 2.7 (0.5) 2.8 (0.6) 2.3 (0.3) 2.4 (0.3)
CD163 1.5 (0.4) 2.0 (0.6) 2.3 (0.6) 3.1 (1.1) 2.4 (0.8) 1.8 (0.4) 1.8 (0.5) 1.9 (0.6) 1.6 (0.4)
Tlr2 2.1 (0.3) 2.3 (0.3) 2.3 (0.3) 2.3 (0.3) 2.2 (0.3) 2.0 (0.2) 1.9 (0.2) 2.0 (0.2) 2.0 (0.2)
Tlr4 6.1 (0.7) 6.5 (0.9) 6.5 (0.9) 6.6 (0.9) 6.5 (0.8) 5.9 (0.8) 6.0 (0.8) 5.9 (0.7) 5.5 (0.8)
MarCO 9 (2) 10 (2) 10 (2) 11 (3) 9 (2) 10 (1) 11 (2) 10 (2) 10 (2)
Notes: Monocyte-derived macrophages from COPD patients (n=6–8) were pretreated for 1 hour with cell media only (not-treated [nT], Haemophilus influenzae [hI], and 
Streptococcus pneumoniae [sP] groups), drug vehicle (V), 10−5 M fluticasone propionate (FP), or 10−5 M budesonide (Bud), prior to incubation with fluorescently labeled HI or 
SP bacteria for 4 hours. Cells were labeled with antibodies against indicated scavenger receptors and receptor expression analyzed by flow cytometry. Data are presented 
as mean (seM). **P0.01 compared to nT.
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however, inhaled FP has been associated with increased 
rates of pneumonia.9–12 This may be due to highly potent 
and prolonged suppression of macrophages and neutrophilic 
functions responsible for bacteria phagocytosis and killing 
after inhalation of FP.
Using an in vitro model, we showed that neither FP 
nor budesonide had effects on phagocytosis of inert beads, 
H. influenzae, or S. pneumoniae by MDMs derived from 
blood monocytes isolated from COPD patients, although 
1 hour’s pretreatment with budesonide at 10−7 M increased 
4-hour phagocytosis of S. pneumoniae significantly by 
approximately 20%, and a trend for a similar increase for 
phagocytosis of both H. influenzae and S. pneumoniae was 
observed after 18 hours’ pretreatment with budesonide in the 
whole concentration range studied (10−10–10−5 M). Although 
there were some differences in effects on phagocytosis 
between FP and budesonide, this was not reflected in the 
overall phagocytic ability of MDMs. However, additional 
effects may have been observed if cells had been cultured 
for longer than 18 hours in CSs prior to assessment of 
phagocytosis. These in vitro data obtained with dissolved 
CSs suggest that the increase in incidence of pneumonia 
in COPD patients treated with FP is not due to changes in 
macrophage-phagocytosis function.
It is well known that CSs inhibit the release of proinflam-
matory cytokines from macrophages, and that this contributes 
to their therapeutic function. We showed that exposure to 
H. influenzae or S. pneumoniae for 4 hours induced the release 
of CXCL8, IL6, and TNFα from MDMs, and that already after 
1 hour’s pretreatment, both FP and budesonide reduced the 
release of these cytokines in a concentration-dependent man-
ner. Nevertheless, there were no statistically significant differ-
ences between the effects of FP and budesonide on cytokine 
release at any time point after exposure to bacteria.
Once a bacterium has been phagocytosed by a mac-
rophage, it undergoes a process known as “bacterial killing”, 
which includes the generation and release of intracellular 
reactive oxygen species and/or proteases to break down 
the bacteria.24 Decreased ability to kill bacteria may result 
in macrophages being overwhelmed by bacteria and lead 
to bacterial colonization and establishment of infection. 
As such, we studied the effects of the two CSs on bacterial 
killing by MDMs. However, neither FP nor budesonide 
altered bacterial killing at 4 hours postinfection, suggest-
ing that this innate immunofunction is not compromised by 
these CSs.
There are few data in the literature regarding the effects 
of CSs on phagocytosis. The data presented in this study 
contrast with earlier work, whereby MDMs exposed to 
dexamethasone showed an increase in phagocytosis and kill-
ing of Staphylococcus aureus via a glucocorticoid-receptor-
dependent mechanism.25 Administration of FP to a murine 
model of Klebsiella pneumoniae infection demonstrated 
increased bacterial load in these animals that was not attrib-
uted to alterations in bacterial phagocytosis or killing, but 
to a suppression in production of nitric oxide and TNFα.26 
Previously, we have shown that budesonide improved phago-
cytosis of both H. influenzae and S. pneumoniae in MDMs 
(five- and threefold, respectively, at 10−6 M);21 however, 
budesonide has also been shown to reduce phagocytosis of 
Escherichia coli in alveolar macrophages.27 The reason for 
these differences for budesonide is not clear; however, they 
may be related to the different incubation times that cells were 
exposed to phagocytic prey in these studies. Zetterlund et al27 
incubated macrophages with bacteria for only 10 minutes, as 
opposed to the 1- and 4-hour incubation periods used in this 
study and the 1-hour period in the study by Taylor et al.21 The 
difference in the effect of budesonide between the present 
study and our previous study could be due to the increased 
statistical power in this study. As both MDMs and alveolar 
macrophages display a similar phagocytic defect,21 we would 
predict that alveolar macrophages would behave similarly 
in response to CSs. However, this would need confirmation 
and was outside the scope of the current study.
In order to determine potential mechanisms of CS action 
on macrophage function, scavenger-receptor expression was 
analyzed. A variety of receptors were analyzed in this study to 
reflect the diverse array of receptors involved in phagocytosis. 
These included the scavenger receptors CD36 and CD163, the 
mannose receptor CD206, the bacteria-recognition receptors 
TLR2 (lipoteichoic acid receptor; Gram-positive bacteria) and 
TLR4 (LPS receptor; Gram-negative bacteria), and MARCO, 
which binds both Gram-positive and -negative bacteria. 
However, none of the receptors analyzed was affected by FP 
or budesonide in the present study. Dexamethasone has been 
shown to increase phagocytosis of latex beads and E. coli by 
MDMs, with an associated increase in expression of scaven-
ger receptors (MARCO, mannose receptors, and CD163).28 
Similarly, in monocytes and MDMs, increased efferocytosis 
in the presence of dexamethasone has been associated with 
increased expression of CD16 and CD163.29 Furthermore, 
dexamethasone-treated cells show a reduction in paxillin pres-
ent in podosomes, associated with reduced tyrosine phospho-
rylation, and a marked increase in levels of Rac.29 Rac proteins 
are critical regulators of phagocytic function involved in actin 
assembly, pseudopod extension, and generation of reactive 
oxygen species for pathogen elimination, and in addition are 
very important in neutrophil migration.30 However, as no 
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change in phagocytosis was seen in this study, this may link 
to the lack of effect on scavenger receptors.
Neutrophils are important phagocytic cells and vital in 
the resolution of lung inflammation. Both FP and budes-
onide have been shown to prolong neutrophil survival by 
inhibiting neutrophil apoptosis.31,32 FP also suppresses neu-
trophil chemotaxis and fibrinogen degradation,33 whereas 
budesonide has no effect on neutrophil chemotaxis.34 This 
suggests that neutrophils are sensitive to CSs, but that FP 
may be more inhibitory than budesonide and contribute to 
the increased risk of pneumonia. We extended our study to 
include examination of neutrophil function; however, simi-
larly to MDMs, neutrophil phagocytosis was not affected 
by exposure to FP or budesonide. This would suggest that 
neutrophil phagocytosis does not influence the increased 
rates of pneumonia in FP-treated COPD patients. There is 
little information regarding the effects of CSs on neutrophil 
phagocytosis of bacterial pathogens. In vivo studies of 
dexamethasone administration in a rat model of acute lung 
injury suggested that dexamethasone had no effect on neu-
trophil phagocytosis, albeit showed a slight suppression of 
oxidative burst.35 In human blood neutrophils, an early study 
showed delayed phagocytosis of Pseudomonas aeruginosa by 
hydrocortisone and methylprednisolone, but dexamethasone 
had no effect, whereas all three CSs showed bactericidal 
effects.36 In a recent study in blood neutrophils from patients 
with ulcerative colitis who had been on high prednisolone 
dosages (10,000 mg), neutrophil phagocytosis of E. coli 
was not impaired compared with neutrophils from patients 
on lower-dose or no prednisolone treatment,37 which is con-
sistent with the lack of effects presented herein.
A limitation of our study in terms of applicability to 
the clinical situation is that we exposed MDMs and neu-
trophils to dissolved CSs, whereas undissolved, particulate 
FP may remain in epithelial lining fluid for many hours 
after inhalation.13 The phagocytosis of particulate FP may 
lead to FP accumulation at extremely high intracellular 
concentrations within phagolysosomes, which may impair 
phagocytosis of bacteria to a greater extent than shown in the 
present in vitro study using dissolved FP. At these very high 
intracellular concentrations, the killing of bacteria by MDMs 
and phagocytosis by neutrophils might also be impaired, 
although no such effects were observed in this study up to 
10−5 M FP concentration. However, it was not possible to 
compare particulate FP in this system.
Conclusion
Our results suggest that dissolved FP and budesonide 
do not have an overall effect on MDM or neutrophil 
phagocytosis of bacteria. However, we cannot exclude 
such effects of particulate FP, which is present in epithelial 
lining fluid for many hours after inhalation. Therefore, 
further study of the effects of particulate FP on functions 
of airway macrophages and neutrophils is warranted, as 
impaired function of these cells may explain or contribute 
to higher rates of pneumonia associated with FP treatment 
compared to budesonide and non-ICS treatments of COPD 
patients.
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Figure S1 Effects of fluticasone propionate or budesonide on viability of MDMs after phagocytosis.
Notes: MDMs from COPD patients (n=20–24) were untreated (UC [untreated control]), or pretreated for 1 hour (A–F) or 18 hours (G–L) with fluticasone propionate ( ), 
budesonide (), or drug vehicle (V) prior to incubation with fluorescently labeled beads or bacteria for 1 hour or 4 hours. Cell viability was measured by MTT assay. Data 
presented as percentage viability compared to UC and shown as mean ± seM; *P0.05 between UC and drug.
Abbreviation: MDMs, monocyte-derived macrophages.
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Figure S2 Flow cytometry gating strategy.
Notes: (A–H) Monocyte-derived macrophages were gated by the forward-scatter (Fsc) vs side-scatter (ssc) population. negative expression was gated on untreated 
population (red) or secondary antibody (MarCO), and a shift to the right indicates positive expression of receptors. graphs show untreated cells (blue), H. influenzae-
positive cells (light green), and cells treated with fluticasone propionate (orange), budesonide (dark green), and vehicle control (pink).
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Table S1 Effects of 18 hours’ pretreatment with fluticasone propionate (FP) or budesonide (Bud) on scavenger-receptor expression
Receptor NT HI HI + V HI + FP HI + Bud SP SP + V SP + FP SP + Bud
Percentage of cells expressing receptors
CD36 41 (13) 50 (8) 59 (8) 60 (7) 49 (8) 41 (19) 41 (9) 35 (8) 39 (8)
CD206 48 (12) 65 (8) 68 (7) 70 (6) 63 (8) 50 (11) 61 (8) 55 (8) 60 (10)
CD163 96 (3) 97 (2) 96 (3) 97 (2) 97 (1) 96 (2) 96 (3) 97 (2) 97 (2)
Tlr2 4 (2) 21 (3)** 28 (5) 27 (6) 26 (4) 6 (2) 7 (2) 9 (4) 9 (4)
Tlr4 2 (1) 20 (4)** 23 (4) 23 (7) 22 (5) 8 (3) 7 (3) 7 (4) 9 (5)
MarCO 17 (16) 39 (16) 35 (7) 35 (16) 37 (19) 58 (11) 53 (14) 45 (14) 50 (13)
Median fluorescence intensity
CD36 5.3 (0.6) 5.3 (0.6) 5.9 (0.7) 5.9 (0.7) 5.3 (0.7) 4.9 (0.6) 5.0 (0.6) 4.8 (0.5) 4.5 (0.5)
CD206 2.1 (0.2) 2.5 (0.5) 2.4 (0.3) 2.4 (0.3) 2.0 (0.3) 2.0 (0.3) 2.0 (0.2) 2.0 (0.2) 2.0 (0.3)
CD163 1.6 (0.3) 1.9 (0.5) 2.4 (0.8) 2.9 (1.0) 2.7 (0.8) 1.6 (0.4) 1.8 (0.5) 2.8 (0.9) 2.4 (0.7)
Tlr2 2.0 (0.2) 2.4 (0.3) 2.4 (0.3) 2.4 (0.3) 2.4 (0.3) 2.0 (0.2) 2.0 (0.2) 2.0 (0.2) 2.3 (0.3)
Tlr4 6.3 (0.7) 6.6 (0.9) 6.6 (0.9) 6.7 (1.0) 6.8 (0.9) 6.0 (0.9) 6.0 (0.8) 6.5 (0.9) 6.5 (0.9)
MarCO 9 (2.0) 10 (2.0) 10 (2.0) 10 (2.0) 10 (2.0) 10 (1.0) 10 (1.0) 10 (2.0) 10 (2.0)
Notes: Monocyte-derived macrophages from COPD patients (n=6–8) were pretreated for 18 hours with cell media only (not-treated [nT], Haemophilus influenzae [hI], and 
Streptococcus pneumoniae [sP] groups), drug vehicle (V), 10−5 M FP or 10−5 M Bud, prior to incubation with fluorescently labeled HI or sP bacteria for 4 hours. Cells were labeled 
with antibodies against scavenger receptors indicated and receptor expression analyzed by flow cytometry. Data expressed as mean (SEM); **P0.01 compared to nT.
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Figure S3 Effects of fluticasone propionate or budesonide on percent phagocytosis of Haemophilus influenzae and Streptococcus pneumoniae by COPD neutrophils.
Notes: Neutrophils from COPD patients were pretreated with fluticasone propionate ( ) or budesonide () at indicated concentrations or drug vehicle (V) for 1 hour and 
subsequently incubated with H. influenzae (A–D) or S. pneumoniae (E–H) for 5, 10, 15, or 60 minutes, cells washed, fixed in 4% paraformaldehyde, and fluorescence measured 
by flow cytometry. Graphs show percentage of neutrophils that phagocytosed bacteria. Data shown as mean ± seM with no statistical differences observed; n=7.
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Figure S4 Effects of fluticasone propionate or budesonide on amount of Haemophilus influenzae and Streptococcus pneumoniae phagocytosed by COPD neutrophils.
Notes: Neutrophils from COPD patients were pretreated with fluticasone propionate ( ) or budesonide () at indicated concentrations or drug vehicle (V) for 1 hour 
and subsequently incubated with H. influenzae (A–D) or S. pneumoniae (E–H) for 5, 10, 15, or 60 minutes, cells washed, fixed in 4% paraformaldehyde, and fluorescence 
measured by flow cytometry. Graphs show the amount of phagocytosed bacteria expressed as median fluorescence intensity (MFI). Data shown as mean ± seM with no 
statistical differences observed; n=7.
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